Meloxicam ameliorates the systemic inflammatory response syndrome associated with experimentally induced endotoxemia in adult donkeys.
Authors: Mendoza Garcia Francisco Javier, Gonzalez-De Cara Carlos, Aguilera-Aguilera Raul, Buzon-Cuevas Antonio, Perez-Ecija Alejandro
Journal: Journal of veterinary internal medicine
Summary
# Editorial Summary: Meloxicam in Equine Endotoxemia Endotoxaemia represents a significant clinical challenge in donkeys, yet therapeutic evidence specific to this species remains scarce. This 2020 study investigated how donkeys mount a systemic inflammatory response to lipopolysaccharide (LPS) challenge and whether meloxicam could modulate this response, using both in vivo experiments in six healthy adult females and ex vivo monocyte cultures. Although LPS induced comparable fever, leukopenia and neutropenia in both treatment groups, animals receiving 0.6 mg/kg IV meloxicam demonstrated substantially reduced plasma lactate concentrations alongside significant attenuation of tumour necrosis factor-alpha and interleukin 1β levels relative to saline controls, despite no observable differences in cytokine mRNA expression—findings supported by meloxicam's direct inhibition of TNF-α release in LPS-stimulated monocyte cultures. For practitioners managing endotoxaemic donkeys presenting with systemic inflammatory complications, these findings suggest meloxicam warrants consideration as an adjunctive anti-inflammatory intervention, though the authors appropriately note that further investigation into post-transcriptional regulation mechanisms and comparative efficacy against other NSAIDs would strengthen clinical decision-making in this understudied population.
Read the full abstract on PubMed
Practical Takeaways
- •Meloxicam may be a useful adjunctive treatment for managing endotoxemia and SIRS in donkeys, particularly for moderating inflammatory cytokine responses and lactate accumulation
- •While meloxicam does not prevent initial acute fever or white blood cell changes from endotoxemia, it appears to reduce the magnitude of systemic inflammation markers
- •Further research is needed comparing meloxicam to other NSAIDs and investigating optimal dosing protocols before making treatment recommendations for clinical endotoxemia cases
Key Findings
- •Meloxicam at 0.6 mg/kg IV significantly attenuated plasma lactate, TNF-α, and interleukin-1β increases compared to saline controls in LPS-induced endotoxemia
- •LPS induced fever, leukopenia, and neutropenia of similar magnitude in both meloxicam and control groups, indicating these acute responses were not mitigated by the NSAID
- •Meloxicam decreased TNF-α release in LPS-activated equine monocyte cultures, suggesting direct anti-inflammatory effects at the cellular level
- •No differences in cytokine mRNA expression were detected between treatment groups, suggesting meloxicam's effects may occur through post-transcriptional regulation mechanisms